Indivior will merge with Supernus, exchanging each Supernus share for 1.5401 Indivior shares and giving Indivior stockholders roughly 56.5% of the combined firm while delivering a $1 billion special Cash Dividend . The transaction expands ownership control, adds cash to shareholders, but introduces a $174 million termination fee risk.

Key Highlights

  • Merger terms give Indivior shareholders 56.5% of the combined company after a 1.5401 exchange ratio.
  • Indivior will issue a $1 billion special cash dividend to shareholders before the merger completes.
  • Citibank has committed a $650 million senior secured term Loan to fund the transaction.

Indivior Pharmaceuticals ( Nasdaq : INDV) announced it will merge with Supernus Pharmaceuticals, converting each Supernus share into 1.5401 Indivior shares. The deal will leave Indivior owners with about 56.5% of the combined firm, while a $1 billion special cash dividend will be paid to shareholders prior to closing. A $650 million senior secured term loan from Citibank will help finance the transaction, and a $174 million termination fee applies if the merger collapses under certain conditions.

Merger Agreement Details

The merger agreement, signed on August 1, 2026, calls for Merger Sub to fold into Supernus, which will survive as a Wholly Owned Subsidiary of Indivior. Upon closing, the surviving entity will be renamed Supernus, Inc. The exchange ratio of 1.5401 means every Supernus share converts into more than one and a half Indivior shares, effectively diluting but increasing the share count. The board of the combined company will consist of eight directors, split evenly between nominees of the two legacy firms, with Jack A. Khattar remaining CEO.

The merger hinges on customary approvals, including Shareholder votes and antitrust clearance. The structure guarantees that existing Indivior shareholders become the majority owners, shaping post‑deal governance.

Ownership, Dividend and Financing Mechanics

Under the agreement, Indivior shareholders will control roughly 56.5% of the new Supernus entity, while Supernus shareholders will hold about 43.5%. The special cash dividend totals $1 billion, payable to holders of record immediately before the effective time, providing immediate Liquidity . To support the Capital needs, Citibank has pledged a senior secured term loan of $650 million, adding Debt capacity without immediately impacting Equity .

The contract also imposes a $174 million termination fee on Indivior if the deal falls apart for specified reasons, creating a financial backstop that may affect future cash flows. The combination of dividend payout and financing underscores a strategic push to consolidate market position while managing balance‑sheet Leverage .

Market Reaction and Positioning

The stock’s 52‑week range of $20.66 to $42.81 shows ample room for price appreciation, while short interest of 7.6 days of average Volume signals a modestly neutral short‑seller stance. The $1 billion dividend and the sizable loan Facility enhance the company’s cash profile, which may attract income‑focused investors and improve the firm’s leverage ratios. Nonetheless, the $174 million termination fee represents a contingent Liability that could weigh on profitability if the transaction fails.

Upcoming Shareholder Vote and Next Steps

The next critical milestone is the shareholder meeting where both Indivior and Supernus investors must approve the merger and the associated Indivior share issuance. Approval of the $1 billion Special Dividend and the $650 million financing package will also be confirmed at that meeting. Investor attention will focus on the outcomes of those votes, as the finalization of the merger and the receipt of the cash dividend depend on them.

The eventual completion of the deal will determine the combined company’s market positioning and financial outlook.

Analysis based on the Form 8-K filed 3 August 2026; figures verified against the filing and live market data.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making Investment decisions.